Akebia Therapeutics Inc
Veridion Score
Composite trend over time
Why is AKBA moving today?
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AKBA.
AKBA insider activity
Akebia Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$629K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-29 | Ostrowski Erik | Insider | sell | $1.11 | 56,019 | 616,616 | $62K | SEC Form 4 |
| 2026-03-05 | 2026-03-04 | Butler John P. | Insider | buy | $1.25 | 69,270 | 3,367,064 | $87K | SEC Form 4 |
| 2026-02-04 | 2026-02-02 | Rucci Carolyn M. | Insider | sell | $1.39 | 27,544 | 588,378 | $38K | SEC Form 4 |
| 2026-02-04 | 2026-02-02 | Rucci Carolyn M. | Insider | sell | $1.39 | 25,382 | 615,922 | $35K | SEC Form 4 |
| 2026-02-04 | 2026-02-02 | Rucci Carolyn M. | Insider | sell | $1.39 | 16,846 | 641,304 | $23K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 13 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAKBA contract awards, year to date.
Public federal awards linked to this ticker.
AKBA lobbying filings, year to date.
Registered lobbying filings matched to Akebia Therapeutics Inc.